Updating results

111 results for metastatic breast cancer Sort: Relevance | Date

Gemcitabine for the treatment of metastatic breast cancer (TA116)

Evidence-based recommendations on gemcitabine (Gemzar) for treating metastatic breast cancer

Technology appraisal guidance Published January 2007

Breast cancer (advanced or metastatic) - lapatinib [ID20]

In development [GID-TAG387] Expected publication date: TBC

Technology appraisal guidance In development

Fulvestrant for the treatment of locally advanced or metastatic breast cancer (TA239)

Evidence-based recommendations on fulvestrant (Faslodex) for treating locally advanced or metastatic breast cancer

Technology appraisal guidance Published December 2011

Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (TA263)

Evidence-based recommendations on bevacizumab (Avastin) in combination with capecitabine for the first-line treatment of metastatic breast cancer

Technology appraisal guidance Published August 2012

Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (TA214)

Evidence-based recommendations on bevacizumab (Avastin) in combination with a taxane for the first-line treatment of metastatic breast cancer

Technology appraisal guidance Published February 2011

Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]

In development [GID-TAG403] Expected publication date: TBC

Technology appraisal guidance In development

Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TA423)

Evidence-based recommendations on eribulin (Halaven) for treating locally advanced or metastatic breast cancer after 2 or more types of chemotherapy

Technology appraisal guidance Published December 2016

Breast cancer (advanced or metastatic) hormone-sensitive - lapatinib [ID115]

In development [GID-TAG404] Expected publication date: TBC

Technology appraisal guidance In development

ESNM13: Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumab

Summary of the evidence on subcutaneous trastuzumab for HER2-positive breast cancer to inform local NHS planning and decision-making

Evidence summary Published March 2013

Breast cancer (HER2 negative, metastatic) - bevacizumab (2nd line) [ID488]

In development [GID-TAG432] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (HER2 positive, metastatic) - pertuzumab (with trastuzumab and docetaxel) [ID523]

In development [GID-TAG322] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (locally advanced, metastatic) - eribulin (after chemotherapy) [ID964]

In development [GID-TA10030] Expected publication date: 21 December 2016

Technology appraisal guidance In development

Eribulin for treating locally advanced or metastatic breast cancer after one prior chemotherapy regimen [ID1072]

In development [GID-TA10094] Expected publication date: TBC

Technology appraisal guidance In development

Fulvestrant for untreated hormone-receptor positive metastatic breast cancer [ID951]

In development [GID-TA10106] Expected publication date: 28 February 2018

Technology appraisal guidance In development

Bone loss (therapy-induced) in non-metastatic breast cancer - denosumab [ID83]

In development [GID-TAG411] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (metastatic) -trastuzumab (as monotherapy and in combination with a taxane) [ID345]

In development [GID-TAG417] Expected publication date: 01 October 2011

Technology appraisal guidance In development

Breast cancer (ErbB2 HER2, metastatic) - lapatinib (with paclitaxel, 1st line) [ID517]

In development [GID-TAG436] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (advanced and/or metastatic) - sunitinib (in combination with capecitabine) [ID319]

In development [GID-TAG410] Expected publication date: TBC

Technology appraisal guidance In development

Advanced breast cancer

Everything NICE has said on diagnosing and treating advanced breast cancer in an interactive flowchart

NICE Pathway Published May 2011 Last updated August 2017

Early and locally advanced breast cancer

Everything NICE has said on diagnosing and treating early and locally advanced breast cancer in an interactive flowchart

NICE Pathway Published May 2011 Last updated August 2017

Bevacizumab in combination with a taxane is not recommended for the first-line treatment of metastatic breast cancer.

Do Not Do Recommendation   Bevacizumab in combination with a taxane is not recommended for the first-line treatment of metastatic...

Do not do recommendation Published June 2015

Advanced breast cancer: diagnosis and treatment (CG81)

Evidence-based recommendations on diagnosing and treating advanced (stage 4) breast cancer (invasive adenocarcinoma) for women and men

Clinical guideline Published February 2009 Last updated August 2017

Metastatic malignant disease of unknown primary origin

Everything NICE has said on diagnosing and managing metastatic malignant disease of unknown primary origin in an interactive flowchart

NICE Pathway Published January 2013 Last updated March 2017

Metastatic malignant disease of unknown primary origin in adults: diagnosis and management (CG104)

Evidence-based recommendations on diagnosing and managing metastatic malignant disease (cancer) of unknown primary origin in adults

Clinical guideline Published July 2010

Eribulin is not recommended, within its licensed indication, for the treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens for advanced disease.

Do Not Do Recommendation   Eribulin is not recommended, within its licensed indication, for the treatment of locally advanced or...

Do not do recommendation Published June 2015

Lapatinib in combination with an aromatase inhibitor is not recommended for first-line treatment in postmenopausal women with metastatic hormonereceptor- positive breast cancer that overexpresses human epidermal growth factor receptor 2 (HER2).

Do Not Do Recommendation   Lapatinib in combination with an aromatase inhibitor is not recommended for first-line treatment in postmenopausal...

Do not do recommendation Published June 2015

Trastuzumab in combination with an aromatase inhibitor is not recommended for first-line treatment in postmenopausal women with metastatic hormonereceptor- positive breast cancer that overexpresses human epidermal growth factor receptor 2 (HER2).

Do Not Do Recommendation   Trastuzumab in combination with an aromatase inhibitor is not recommended for first-line treatment in postmenopausal...

Do not do recommendation Published June 2015

Trastuzumab emtansine is not recommended, within its marketing authorisation, for treating adults with human epidermal growth factor 2 (HER2) positive, unresectable locally advanced or metastatic breast cancer previously treated with trastuzumab and a taxane.

Do Not Do Recommendation   Trastuzumab emtansine is not recommended, within its marketing authorisation, for treating adults with human...

Do not do recommendation Published February 2016

Microwave ablation for treating primary lung cancer and metastases in the lung (IPG469)

Evidence-based recommendations on microwave ablation for treating primary lung cancer and metastases in the lung

Interventional procedures guidance Published November 2013

Guidance on the use of trastuzumab for the treatment of advanced breast cancer (TA34)

Evidence-based recommendations on the use of trastuzumab (Herceptin) for the treatment of advanced breast cancer

Technology appraisal guidance Published March 2002

Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (TA458)

Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for treating advanced HER2-positive breast cancer that has been treated before

Technology appraisal guidance Published July 2017

Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)

Evidence-based recommendations on pertuzumab (Perjeta) for HER2-positive breast cancer in adults

Technology appraisal guidance Published December 2016

Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours (TA265)

Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours

Technology appraisal guidance Published October 2012

Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer (TA107)

Evidence-based recommendations on trastuzumab (Herceptin) for adjuvant treatment of early-stage HER2-positive breast cancer

Technology appraisal guidance Published August 2006 Last updated March 2014

Early and locally advanced breast cancer: diagnosis and treatment (CG80)

Evidence-based recommendations on diagnosing and treating early and locally advanced (stage 1 & 2) breast cancer (adenocarcinoma) for women and men

Clinical guideline Published February 2009 Last updated March 2017

Colorectal cancer: diagnosis and management (CG131)

Evidence-based recommendations on diagnosing and managing colorectal cancer (cancer of the colon and the rectum) in adults

Clinical guideline Published November 2011 Last updated December 2014

Breast cancer (hormone-receptor positive, HER2-negative) - palbociclib [ID915]

In development [GID-TA10068] Expected publication date: TBC

Technology appraisal guidance In development

Metastatic spinal cord compression

Everything NICE has said on diagnosing and managing adults at risk of, or with, metastatic spinal cord compression in an interactive flowchart

NICE Pathway Published January 2012 Last updated July 2017

Metastatic spinal cord compression in adults: risk assessment, diagnosis and management (CG75)

Evidence-based recommendations on the risk assessment, diagnosis and management of metastatic spinal cord compression (MSCC) in adults with cancer

Clinical guideline Published November 2008

Past appeals and decisions

Down to Rejected appeals Cancelled appeals Past appeals TA ID Appraisal Short title Appeal hearing date TA111 Alzheimer´s disease - donepezil,...

Published May 2017

Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (TA208)

Evidence-based recommendations on trastuzumab (Herceptin) for treating adenocarcinoma (HER2-positive metastatic gastric cancer/stomach cancer)

Technology appraisal guidance Published November 2010

Irreversible electroporation for treating primary lung cancer and metastases in the lung (IPG441)

Evidence-based recommendations on irreversible electroporation (IRE) for treating primary lung cancer and metastases in the lung

Interventional procedures guidance Published February 2013

Block scoping reports

If you have any questions about this page please email Michelle Adhemar - michelle.adhemar@nice.org.uk   Batch 52 block scoping report Batch 52...

Published June 2017